MaxCyte (MXCT) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
MaxCyte, Inc. has appointed Cynthia Collins to its Board of Directors, enhancing its leadership with her extensive experience in cell therapy and genetic medicine. Collins, who has a notable background as CEO of several biotech companies, will serve on the board’s compensation committee. This appointment aligns with MaxCyte’s strategy to advance its cell engineering platform and support the development of next-generation cell-based therapies.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
